Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone512-219-8020
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$315.82 million
Profitability
Miscellaneous
Employees988
Next Earnings Date8/5/2019 (Estimated)
OptionableOptionable
Luminex (NASDAQ:LMNX) Frequently Asked Questions
What is Luminex's stock symbol?
Luminex trades on the NASDAQ under the ticker symbol "LMNX."
How often does Luminex pay dividends? What is the dividend yield for Luminex?
Luminex declared a quarterly dividend on Monday, February 11th. Investors of record on Thursday, March 21st will be paid a dividend of $0.06 per share on Thursday, April 11th. This represents a $0.24 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Wednesday, March 20th. View Luminex's Dividend History.
How were Luminex's earnings last quarter?
Luminex Co. (NASDAQ:LMNX) released its quarterly earnings results on Monday, May, 6th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.07 by $0.14. The medical instruments supplier earned $82.41 million during the quarter, compared to analyst estimates of $83.10 million. Luminex had a return on equity of 1.62% and a net margin of 2.55%. The business's revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.30 earnings per share. View Luminex's Earnings History.
When is Luminex's next earnings date?
What price target have analysts set for LMNX?
3 brokers have issued 1 year target prices for Luminex's stock. Their predictions range from $27.00 to $33.00. On average, they expect Luminex's stock price to reach $30.00 in the next year. This suggests a possible upside of 44.5% from the stock's current price. View Analyst Price Targets for Luminex.
What is the consensus analysts' recommendation for Luminex?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.
Has Luminex been receiving favorable news coverage?
Headlines about LMNX stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Luminex earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are some of Luminex's key competitors?
Some companies that are related to Luminex include NuVasive (NUVA), Merit Medical Systems (MMSI), Cantel Medical (CMD), Glaukos (GKOS), Nevro (NVRO), Irhythm Technologies (IRTC), Atrion (ATRI), Shockwave Medical (SWAV), Mazor Robotics (MZOR), Silk Road Medical (SILK), Cardiovascular Systems (CSII), K2M Group (KTWO), AtriCure (ATRC), Cryolife (CRY) and Orthofix Medical (OFIX).
What other stocks do shareholders of Luminex own?
Who are Luminex's key executives?
Luminex's management team includes the folowing people:
- Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
- Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
- Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
- Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
- Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)
Who are Luminex's major shareholders?
Luminex's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.47%), Renaissance Technologies LLC (5.25%), Dimensional Fund Advisors LP (4.51%), Acadian Asset Management LLC (2.79%), Neuberger Berman Group LLC (2.24%) and Investment Management of Virginia LLC (2.02%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.
Which institutional investors are selling Luminex stock?
LMNX stock was sold by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC, Acadian Asset Management LLC, Goldman Sachs Group Inc., JPMorgan Chase & Co., First Trust Advisors LP, Burney Co., Eqis Capital Management Inc. and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro and G Walter Loewenbaum II. View Insider Buying and Selling for Luminex.
Which institutional investors are buying Luminex stock?
LMNX stock was acquired by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, Kennedy Capital Management Inc., Marshall Wace LLP, Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Neuberger Berman Group LLC, Bank of Montreal Can and Marshall Wace North America L.P.. View Insider Buying and Selling for Luminex.
How do I buy shares of Luminex?
Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Luminex's stock price today?
One share of LMNX stock can currently be purchased for approximately $20.76.
How big of a company is Luminex?
Luminex has a market capitalization of $933.72 million and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.51 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 988 workers across the globe.
What is Luminex's official website?
How can I contact Luminex?
Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]
MarketBeat Community Rating for Luminex (NASDAQ LMNX)
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
